CRISPRMED25 Poster Prize Winners Highlight Diverse...
Apr. 22, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Voyager Therapeutics
Company Type: Therapeutics
Main focus: Development of new adeno-asssociated virus (AAV) serotypes to target the central nervous system
Company stage: Pre-clinical
Diseases: Neurodegenerative disorders
Genome-editing tool: CRISPR-Cas
Funding stage: IPO
Location: Cambridge (Mass.), USA
Website: https://www.voyagertherapeutics.com
Pipeline: https://www.voyagertherapeutics.com/pipeline/
Partners: Sangamo, Pfizer, Novartis
Voyager Therapeutics is a pre-clinical-stage biotech whose main technology TRACER® allows for screening and identification of new adeno-associated virus (AAV) serotypes with better capabilities to reach the central nervous system. Improved AAVs can been loaded with various cargoes, including RNAi and CRISPR-Cas reagents. Voyager Therapeutics is targeting a number of diseases including Alzheimer's and Parkinson’s disease.
